ORTHOPEDIATRICS CORP Q3 FY2026 earnings call

• Financial Performance & Guidance: Delivered record revenue of $72.7 million (+19% YoY). Raised full-year 2026 revenue guidance to $270–$273 million (14–16% growth). Reiterated adjusted EBITDA guidance of ~$25 million. Achieved positive free cash flow ($1.6M) for the second consecutive quarter.
• Innovation Super Cycle: Early-stage products like 3P Hip, Traxio, and VertiGlide are contributing to revenue. The company is deploying instrument sets judiciously to maintain free cash flow breakeven or better in 2026 and positivity thereafter. Full impact of limited-launch products is expected in 2027 and beyond.
• Product Launches & Pipeline:
  • 3P Platform: 3P Hip is in full commercial launch; 3P Small and Mini are in limited launch with full release expected H1 2027.
  • Nailing: PNP Tibia continues strong growth; PNP Retrograde launched with first cases in Oct 2026, targeting full commercialization mid-2027.
  • OPSB (Specialty Bracing): Grew >20%. Launched PD Hip Rigid Brace (Hippo) and Knee Tractor Fix. Expanded clinic footprint to 60+ clinics (from 31 at start of year). DF2 adoption is near-universal in US children's hospitals.
  • Scoliosis: VertiGlide adoption accelerating (~125 surgeons trained). Ellie (electromechanical growing implant) targeted for early inpatient procedures in early 2027; Varaxis fusion system beta launch planned next year.
• Operational Efficiency: Gross margin held steady at 74%. Operating leverage improved as revenue grew faster than operating expenses. Sales & Marketing expense increase was largely due to distributor kicker commissions that will normalize in Q4.
• International Expansion: EU MDR approvals enabling rollout of legacy products in Europe. Osseo partnership leverages existing commercial infrastructure. LAT-SAM growth tempered by conservative credit management in Brazil.

• Trauma and Deformity: Revenue of $52.6 million, up 19% year-over-year (YoY). This segment represents approximately 72% of total revenue. Growth was driven by share gains in legacy implants (cannulated screws, PMP femur, PD plates), the addition of the new 3P HIP system, and continued OPSB growth.
• Scoliosis: Revenue of $19.2 million, up 18% YoY. Represents approximately 26% of total revenue. Growth was primarily driven by increased adoption of VertiGlide and Response Fusion systems.
• International: Revenue of $14.8 million, up 18% YoY. Represents approximately 20% of total revenue. Strong performance in EMEA (driven by legacy product demand and EU MDR approvals) partially offset by timing headwinds in LAT-SAM regarding set sales.
• Sports Medicine/Other: Revenue of $0.9 million, up slightly from $0.8 million YoY. Represents less than 2% of total revenue.

• Full-Year 2026 Revenue: Raised to $270–$273 million, representing 14–16% growth.
• Adjusted EBITDA: Reiterated at approximately $25 million.
• Free Cash Flow: Expected to be breakeven or better for 2026, and positive in 2027 and beyond.
• Capital Deployment: Expect to deploy approximately $10 million in instrument sets for the full year.
• Q4 Outlook: Management indicated conservatism in Q4 guidance due to potential lack of large one-time events (like 7D unit sales or Brazil set sales seen in prior year Q4), though underlying volume remains strong.

• Instrument Set Deployment Risks: Aggressive deployment impacts free cash flow; management must balance growth against cash usage. Limited availability of some super-cycle products creates scarcity but requires careful capital allocation.
• New Product Adoption Uncertainty: Products like Ellie and Varaxis face regulatory hurdles (FDA IDE approval) and may have delayed timelines or limited initial impact.
• International Credit Risk: Conservative approach to LAT-SAM (specifically Brazil) due to accounts receivable concerns, which may temper international growth.
• Margin Pressure: While gross margin remained stable, rapid OPSB growth can pressure gross margins compared to higher-margin implant business, though contribution margins are similar.
• Competitive Landscape: Reliance on gaining market share within legacy contracts; competitors pulling products from market aids Orthopediatrics' position but requires active conversion efforts.

Q: Analyst asked about the sustainability of Q3 S&M expense increases (due to distributor kickers) and whether the business has enough leverage to hit EBITDA/FCF guidance given set spend. / A: CFO Fred Hite explained Q3 S&M was an anomaly due to top partners hitting quota and triggering kicker commissions, which will claw back in Q4. He noted YTD EBITDA grew 60% vs 16% revenue growth. With Q4 last year generating $10M FCF, management is confident they can reach breakeven or better for the full year despite current set deployment costs.

Q: Analyst questioned why Q4 guidance appears conservative given strong volumes and new product launches, asking if the midpoint could be exceeded. / A: CEO David Bailey cited conservatism to avoid over-promising, noting Q4 2025 included unique events like large 7D unit sales and Brazil set sales that may not recur. CFO added that they do not count on sporadic large set sales or 7D units in future guidance to protect profitability metrics, focusing instead on sustainable organic growth from new products ramping in 2027.

Q: Analyst asked how the 'Super Cycle' innovation pipeline contributes to profitability beyond top-line growth, specifically regarding ASPs, mix, and set efficiency. / A: CEO Bailey stated it is 'all of the above.' New products have higher ASPs and margins. They generate negotiating power to pull through legacy products already deployed in hospitals (requiring no new set capital), improving utilization of existing inventory. OPSB products like DF2 offer high margins without any set deployment required, significantly boosting overall P&L and FCF efficiency.

Q: Analyst sought details on OPSB clinic expansion strategy, territory targets, and criteria for selecting new locations. / A: CEO Bailey noted they are ahead of schedule with 60+ clinics, aiming for 27 territories by end of 2027. Criteria prioritize locations with strong existing implant relationships and contracting to ensure rapid profitability. Greenfield sites take longer but are pursued where demand is high. Synergies exist between implant usage and clinic referrals (e.g., VertiGlide users referred to bracing).

Q: Analyst asked for updates on VertiGlide surgeon training numbers, user base composition, and the timeline/probability of Ellie impacting 2027 results. / A: CEO Bailey confirmed ~125 formally trained surgeons, with user base growing via both repeat usage and new adopters. Ellie’s impact is likely limited in 2027 due to FDA IDE approval timing; surgeries are targeted for early 2027, but full market release is a 2028-2029 story. However, feedback is extremely positive, and Ellie combined with VertiGlide positions scoliosis for significant long-term growth.